Biopeople

Born leader

Born leader

16.09.2014 - David Veitch has been appointed as Chief Commercial Officer of Basilea Pharmaceutica International Ltd.

As a member of the management committee, David Veitch will be responsible for leading Basilea's commercial operations, including sales, marketing, pricing and market access. Veitch has over 25 years of international commercial experience in the pharmaceutical industry. Before joining Basilea, he led cross-functional organisations at the country and European level and was responsible for the launch of numerous brands across several therapeutic areas. From 1996 ­to 2011, he was President European Operations at Savient Pharmaceuticals. Veitch has also held various positions at Bristol-Myers Squibb UK and Europe. His last position at the company was Senior Vice President Europe, Middle-East and Asia, Marketing and Brand Commercialization, where he led the commercial organisation for the region with a focus on specialty care brands.

http://www.european-biotechnology-news.com/people/bio-people/2014/david-veitch.html

19.06.2014 Recombinant spider silk producer AMSilk GmbH (Planegg, Germany) has named Jens Klein as its Managing Director.

AmSilk

He succeeds Axel Leimer, who had led the company since 2008. Klein previously worked with industrial biotech company Evonik Industries AG and was a member of the executive board of med-tech, biotech, and high-tech investment company Mulligan BioCapital AG. Prior to Mulligan, he was the commercial head and managing director of subsidiaries of Fresenius AG (Bad Homburg).

17.06.2014 Udit Batra has taken the helm as new CEO and President at Merck Millipore’s Consumer Health Division from Robert Yates, who has left the company.

Lichtbildatelier Eva Speith

Prior to his new position, Batra served as Head of Consumer Health at the German company. The chemical engineer joined Merck Serono from Novartis, where he had held a range of executive management positions since 2006. Before joining Novartis, Batra worked at Merck & Co., McKinsey and Johnson & Johnson.

29.05.2014 Drug discovery provider Sygnature Discovery Ltd. has appointed Gerry Thomas as its new Director of Business Development.

Sygnature

Thomas spent more than 20 years in drug discovery and development at Boots Pharmaceuticals, BASF/Knoll, OSI Pharmaceuticals, Prosidion and Shire Pharmaceuticals. At Sygnature, the medicinal chemist will be instrumental in promoting the company’s integrated drug discovery capabilities and expertise across Europe and North America. 

27.05.2014 Drug giant Sanofi S.A. (Paris) has filled the newly-created position of Chief Patient Officer with Anne C. Beal, a public health specialist with a focus on providing access to high-quality health care.

Sanofi S.A.

Beal’s responsibility will be to infuse the patient perspective in Sanofi’s activities, ranging from early-stage R&D through to market availability of novel healthcare solutions. A pediatrician by profession, Beal joins Sanofi from the Patient Centered Outcomes Research Institute (PCORI), the United States’ largest research institute focused on patient-centered outcomes research, where she was Deputy Executive Director and Chief Officer for Engagement. Prior to PCORI, Beal was president of the Aetna Foundation, the independent charitable and philanthropic arm of Aetna Inc. She holds a B.A. from Brown University, an M.D. from Cornell University Medical College, and an M.P.H. from Columbia University. 

22.05.2014 F. Hoffmann-La Roche has promoted Genentech’s former VP of clinical hematology and oncology Dietmar Berger to lead the pharma giant’s clinical development for oncology and hematology.

Roche

He succeeds Sandra Homing, who was named Chief Medical Officer last January. Berger brings the company more than 20 years of experience in the field. Before joining Roche, he co-led oncology research at Bayer HealthCare AG and at Amgen Inc.

20.05.2014 Alessandra Cervino has joined Paris-based metagenomics specialist Enterome Bioscience SA as Head of Discovery.

Michael Guez

The 38-old reseacher brings the firm over 15 years of experience in the discovery and development of genetic and genomic biomarkers. Before joining Enterome, Cervino was VP R&D and Biostatistics at TCLand Expression, Head of Statistical Sciences at Scripps Florida, and group leader in statistical genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co.

15.05.2014 ADC specialist Glythera (UK) has named Ian Evetts as its new Commercial Director.

Glythera

Evett brings in more than 20 years experience in the pharmaceutical industry with a track record of senior strategic and operational roles, among them Managing Director at Atebion BDS Ltd., Strategic Advisor at Bionure and Business Development and Portfolio Director at AstraZeneca. As Commercial Director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies.

13.05.2014 Isarna Therapeutics GmbH (Munich) has named Elizabeth Czerepak to lead the company’s new office location in New York City as Chief Financial Officer and Chief Business Officer.

Isarna Therapeutics

Czerepak has a track record of 21 years in the biopharma industry and nine years as a venture capital investor at JP Morgan and Bear Stearns. She has served in various executive-level finance, licensing and corporate development positions, most recently as Chief Financial Officer and Principal Accounting Officer at Cancer Genetics, Inc. Prior to CGI, Czerepak worked at BASF Pharma (Knoll), Hoffmann-La Roche and Merck & Co.

06.05.2014 The European Food Safety Authority’s Management Board has nominated Dr. Bernhard Url as EFSA’s next Executive Director.

EFSA

Following the departure of former Director Catherine Geslain-Lanéelle, Url has been EFSA’s acting Executive Director since the autumn of 2013. A qualified veterinarian by training, he brings high-level management experience from public and private food-safety organisations to the role, most recently as Managing Director for the Austrian Agency for Health and Food Safety (AGES). Until March 2012, Url served as a member of EFSA’s Management Board.

29.04.2014 Canbex Therapeutics Ltd has hired Alberto Lledó as its new Chief Medical Officer.

Canbex SL

Lledó will lead Canbex’s preparations in proof-of-concept trials for VSN16R, a small molecule for the treatment of spasticity in multiple sclerosis. Lledó is a Senior Consultant Neurologist at the Clínica Creu Blanca (Barcelona), and spent sixteen years at Eli Lilly. He will take over as Chief Medical Officer from Dr. Miroslav Ravic, who is guiding the company through the completion of its Phase I study. 

Vorherige Seite3/21Nächste Seite

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%
  • ADDEX3.10 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.17 EUR0.00%
  • ACTELION109.60 CHF0.00%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR26.6%
  • EPIGENOMICS3.83 EUR23.2%

FLOP

  • ADDEX3.10 CHF-23.8%
  • EVOTEC3.08 EUR-15.8%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR286.0%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • BIOFRONTERA2.20 EUR-39.7%
  • MERCK KGAA68.48 EUR-39.7%

No liability assumed, Date: 19.09.2014


Current issue

All issues

Product of the week

Products